Nasal Sprays Could Deliver Peptide Drugs Directly to the Brain to Treat Alzheimer's
Delivering therapeutic peptides through the nose bypasses the blood-brain barrier and could enable a new class of non-invasive Alzheimer's treatments — though clinical validation is still needed.
Quick Facts
What This Study Found
Intranasal delivery of therapeutic peptides can bypass the blood-brain barrier through nose-to-brain pathways, offering a non-invasive route to deliver Alzheimer's disease treatments directly to the brain. The review identifies key advantages: enhanced stability, rapid absorption, non-invasiveness, and improved patient compliance compared to injection-based delivery. Nanoparticle formulations can further improve the efficacy of intranasally delivered peptides by protecting them from degradation and enhancing their transport through nasal pathways.
Therapeutic peptides targeting critical AD pathological processes — including amyloid aggregation, tau phosphorylation, and neuroinflammation — are promising candidates for this delivery route. However, advancing from encouraging preclinical results to clinical applications remains the central challenge.
Key Numbers
AD = ~60% of dementia cases · nose-to-brain pathway bypasses BBB · non-invasive delivery · nanoparticle enhancement
How They Did This
Review covering Alzheimer's disease mechanisms, existing therapies, brain targeting challenges, nose-to-brain delivery pathways, and recent advances in intranasal peptide delivery technologies including nanoparticle-based formulations.
Why This Research Matters
Alzheimer's disease accounts for nearly 60% of all dementia cases, yet current treatments only manage symptoms. Many promising peptide drugs fail because they can't cross the blood-brain barrier — the brain's protective wall that blocks most drugs. Nasal delivery offers a shortcut that bypasses this barrier entirely, potentially enabling a new generation of peptide-based Alzheimer's treatments that are both effective and easy to administer.
The Bigger Picture
The nose-to-brain delivery route is gaining traction across neurodegenerative diseases, not just Alzheimer's. If intranasal peptide delivery proves clinically effective, it could open the door to treating Parkinson's, ALS, and other brain diseases with peptide drugs that currently can't reach their target. The combination of therapeutic peptides with nanoparticle delivery through nasal pathways represents a convergence of three active research fields — peptide therapeutics, nanotechnology, and alternative drug delivery routes.
What This Study Doesn't Tell Us
Most evidence for intranasal peptide delivery in AD comes from preclinical animal studies. Translation to humans is complicated by anatomical differences in nasal passages, the challenge of consistent dosing, and the lack of long-term safety data for chronic nasal peptide administration. The blood-brain barrier bypass through nasal delivery is well-established in animals but less proven in human clinical settings for peptide-sized molecules.
Questions This Raises
- ?Which specific therapeutic peptides for Alzheimer's are closest to intranasal clinical trials in humans?
- ?How does chronic daily nasal peptide administration affect nasal mucosa integrity over months and years?
- ?Can intranasal peptide delivery achieve therapeutic concentrations in deeper brain regions affected by Alzheimer's, not just superficial areas?
Trust & Context
- Key Stat:
- ~60% of dementia Alzheimer's disease accounts for approximately 60% of all dementia cases, yet current treatments only manage symptoms — creating an urgent need for drug delivery innovations
- Evidence Grade:
- This is a comprehensive review published in Biomaterials Advances that covers the theoretical basis and preclinical evidence for intranasal peptide delivery in AD. While the approach is scientifically sound, clinical validation in human Alzheimer's patients is still lacking.
- Study Age:
- Published in 2026 in Biomaterials Advances. Extremely current, representing the latest thinking on intranasal peptide delivery for neurodegenerative disease.
- Original Title:
- Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease.
- Published In:
- Biomaterials advances, 178, 214474 (2026)
- Authors:
- Majie, Ankit, Karmakar, Varnita, Ghosh, Arya, Chakraborty, Snigdha, Apurva, Layek, Buddhadev, Gorain, Bapi
- Database ID:
- RPEP-15645
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How can a nasal spray deliver drugs to the brain?
The upper part of your nasal cavity has direct nerve connections to the brain (the olfactory and trigeminal nerves). Drugs sprayed into the nose can travel along these nerve pathways directly into brain tissue, completely bypassing the blood-brain barrier that blocks most drugs taken by mouth or injection.
Why use peptides for Alzheimer's instead of regular drugs?
Peptides can target specific disease processes in Alzheimer's — like the protein clumps (amyloid plaques) and twisted fibers (tau tangles) that damage brain cells. They're more precise than small molecule drugs but normally can't reach the brain because the blood-brain barrier blocks them. Nasal delivery solves this barrier problem.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-15645APA
Majie, Ankit; Karmakar, Varnita; Ghosh, Arya; Chakraborty, Snigdha; Apurva; Layek, Buddhadev; Gorain, Bapi. (2026). Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease.. Biomaterials advances, 178, 214474. https://doi.org/10.1016/j.bioadv.2025.214474
MLA
Majie, Ankit, et al. "Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease.." Biomaterials advances, 2026. https://doi.org/10.1016/j.bioadv.2025.214474
RethinkPeptides
RethinkPeptides Research Database. "Advanced intranasal peptide delivery systems for improved ma..." RPEP-15645. Retrieved from https://rethinkpeptides.com/research/majie-2026-advanced-intranasal-peptide-delivery
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.